Clinical and Biological Data
| . | . | . | . | . | . | . | . | EBV . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | (serology-IgG) . | ||||||
| . | . | . | . | . | . | . | . | . | . | |||||
| . | Age/Sex . | B Symptoms . | Organ Involvement . | Stage . | β2M . | LDH . | VIH-HTLV 1 (serology) . | Anti-VCA . | Anti-EBNA . | CBF . | Karyotype . | . | Outcome* . | |
| . | . | . | . | . | . | . | . | . | . | . | . | Treatment . | . | |
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
| Case no. 1 | 39/F | + | Ovaries, womb, ileum, ascites, bulky pelvic mass | IV | 2 | 569 | − | 1:320 | 1:20 | − | ND | CVP | Partial response | |
| VCAP | ||||||||||||||
| (3 courses) | ||||||||||||||
| ESAP | ||||||||||||||
| Failure | D (3 mo) | |||||||||||||
| Case no. 2 | 29/M | + | Bone marrow, | |||||||||||
| lymph nodes, | ||||||||||||||
| femur, spleen | IV | 2, 6 | 975 | − | 1:320 | 1:20 | − | 46 XY | CVP | Complete response | A (14 mo) | |||
| CHOP-MTX | ||||||||||||||
| ARA.C-VP16 | ||||||||||||||
| Allo-BMT | ||||||||||||||
| Case no. 3 | 28/M | + | Bone marrow, spleen liver, | |||||||||||
| lymph nodes, | ||||||||||||||
| ascitis | IV | 5, 7 | 3,100 | − | 1:1280 | 1:20 | − | 46 XY | CVP | |||||
| CHOP-MTX | ||||||||||||||
| ESAP | ||||||||||||||
| ARA.C-IDA | ||||||||||||||
| + Quinine | Failure | D (2 mo) | ||||||||||||
| . | . | . | . | . | . | . | . | EBV . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | (serology-IgG) . | ||||||
| . | . | . | . | . | . | . | . | . | . | |||||
| . | Age/Sex . | B Symptoms . | Organ Involvement . | Stage . | β2M . | LDH . | VIH-HTLV 1 (serology) . | Anti-VCA . | Anti-EBNA . | CBF . | Karyotype . | . | Outcome* . | |
| . | . | . | . | . | . | . | . | . | . | . | . | Treatment . | . | |
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
| Case no. 1 | 39/F | + | Ovaries, womb, ileum, ascites, bulky pelvic mass | IV | 2 | 569 | − | 1:320 | 1:20 | − | ND | CVP | Partial response | |
| VCAP | ||||||||||||||
| (3 courses) | ||||||||||||||
| ESAP | ||||||||||||||
| Failure | D (3 mo) | |||||||||||||
| Case no. 2 | 29/M | + | Bone marrow, | |||||||||||
| lymph nodes, | ||||||||||||||
| femur, spleen | IV | 2, 6 | 975 | − | 1:320 | 1:20 | − | 46 XY | CVP | Complete response | A (14 mo) | |||
| CHOP-MTX | ||||||||||||||
| ARA.C-VP16 | ||||||||||||||
| Allo-BMT | ||||||||||||||
| Case no. 3 | 28/M | + | Bone marrow, spleen liver, | |||||||||||
| lymph nodes, | ||||||||||||||
| ascitis | IV | 5, 7 | 3,100 | − | 1:1280 | 1:20 | − | 46 XY | CVP | |||||
| CHOP-MTX | ||||||||||||||
| ESAP | ||||||||||||||
| ARA.C-IDA | ||||||||||||||
| + Quinine | Failure | D (2 mo) | ||||||||||||
Abbreviations: β2m, β2 microglobuline (N < 2.4 mg/L); LDH, n < 420; CBF, cerebral blood fluid; CVP, cyclophosphamide, vincristine, and prednisone; CHOP-MTX, cyclophosphamide, adriblastine, prednisone, and methotrexate; ESAP, VP16, cytarabine, cisplatinum; ARA.C-IDA, cytarabine, idarubicine; D, dead; A, alive; ND, not done.
After admission.